Drug Profile
IRX 4204
Alternative Names: AGN-194204; ALRT-4204; IRX-4204; NRX-194204; NRX-4204; VTP-194204Latest Information Update: 16 Feb 2024
Price :
$50
*
At a glance
- Originator Allergan
- Developer Icahn School of Medicine at Mount Sinai; Io Therapeutics
- Class Antihyperglycaemics; Antineoplastics; Antiparkinsonians; Small molecules; Tetrahydronaphthalenes
- Mechanism of Action Immunomodulators; Nuclear receptor subfamily 4 group A member 2 agonists; Retinoid X receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Prostate cancer
- Phase I Breast cancer
- No development reported Alzheimer's disease; Multiple sclerosis; Non-small cell lung cancer; Parkinson's disease
Most Recent Events
- 05 Dec 2023 Pharmacodynamics data from a preclinical study in Breast cancer presented at the 46th Annual San Antonio Breast Cancer Symposium (SABCS-2023)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Recurrent, Second-line therapy or greater) in USA (PO)
- 07 Apr 2022 Io Therapeutics in collaboration with Dartmouth College suspends a phase I trial in Non-small cell lung cancer (Late-stage disease, Combination therapy, Recurrent, Second-line therapy or greater) in USA (PO) (NCT02991651)